

~~FILED
OFFICE OF THE
SECRETARY
2008 JAN 10 P 3:04
FEDERAL ENERGY
REGULATORY COMMISSION~~



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0379
Expires:	February 28, 2010
Estimated average burden hours per response	2.0

SE6
Mail Processing
Section

JAN 11 2008

FORM F-X

APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING
Washington, DC
101

GENERAL INSTRUCTIONS

I. Form F-X shall be filed with the Commission:

- (a) by any issuer registering securities on Form F-8, F-9, F-10 or F-80 under the Securities Act of 1933;
- (b) by any issuer registering securities on Form 40-F under the Securities Exchange Act of 1934 (the "Exchange Act");
- (c) by any issuer filing a periodic report on Form 40-F, if it has not previously filed a Form F-X in connection with the class of securities in relation to which the obligation to file a report on Form 40-F arises;
- (d) by any issuer or other non-U.S. person filing tender offer documents on Schedule 13E-4F, 14D-1F or 14D-9F;
- (e) by any non-U.S. person acting as trustee with respect to securities registered on Form F-7, F-8, F-9, F-10, F-80, or SB-2; and
- (f) by a Canadian issuer qualifying an offering statement pursuant to the provisions of Regulation A, or reg
- (g) by any non-U.S. issuer providing Form CB to the Commission in connection with a tender offer, rights offering or business combination.

A Form F-X filed in connection with any other Commission form should no be bound together with or be included only as an exhibit to, such other form.

II. Six copies of the Form F-X, one of which must be manually signed, shall be filed with the Commission as its principal office.

A. Name of issuer or person filing ("Filer"): Pharmexa A/S

B. (1) This is [check one]

- an original filing for the Filer
- an amended filing for the Filer

(2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rule 101(b)(9)

PROCESSED

JAN 22 2008

B
THOMSON
FINANCIAL

Note: Regulation S-T Rule 101(b)(9) only permits the filing of the Form F-X in paper:

- (a) if the party filing or submitting the Form CB is not subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; or

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(b) if filed by a Canadian issuer when qualifying an offering statement pursuant to the provisions of Regulation A (230.251 - 230.263 of this chapter).

- (3) A filer may also file the Form F-X in paper under a hardship exemption provided by Regulation S-T Rule 201 or 202 (17 CFR 232.201 or 232.202). When submitting the Form F-X in paper under a hardship exemption, a filer must provide the legend required by Regulation S-T Rule 201(a)(2) or 202(c) (17 CFR 232.201(a)(2) or 232.202(c)) on the cover page of the Form F-X.

C. Identify the filing in conjunction with which this Form is being filed:

Name of registrant Pharmexa A/S

Form type CB

File Number (if known) N/A

Filed by Pharmexa A/S

Date Filed (if filed concurrently, so indicate) January 10, 2008

D. The Filer is incorporated or organized under the laws of (Name of the jurisdiction under whose laws the issuer is organized or incorporated Denmark and has its principal place of business at (Address in full and telephone number)

**Kogle Allé 6
DK-2970 Hørsholm
Denmark
+ (45) 45 16 25 25**

E. The Filer designates and appoints (Name of United States person serving as agent) C.T. Corporation System ("Agent") located at (Address in full in the United States and telephone number)

**111 Eighth Avenue
New York NY 10011
USA**

as the agent of the Filer upon whom may be served any process, pleadings, subpoenas, or other papers in

(a) any investigation or administrative proceeding conducted by the Commission; and

(b) any civil suit or action brought against the Filer or to which the Filer has been joined as defendant or respondent, in any appropriate court in any place subject to the jurisdiction of any state or of the United States or of any of its territories or possessions or of the District of Columbia, where the investigation, proceeding or cause of action arises out of or relates to or concerns (i) any offering made or purported to be made in connection with the securities registered or qualified by the Filer on Form (Name of form) CB on (Date) January 10, 2008 or any purchases or sales of any security in connection therewith; (ii) the securities in relation to which the obligation to file an annual report on Form 40-F arises, or any purchases or sales of such securities; (iii) any tender offer for the securities of a Canadian issuer with respect to which filings are made by the Filer with the Commission on Schedule 13E-4F, 14D-1F or 14D-9F; or (iv) the securities in relation to which the Filer acts as trustee pursuant to an exemption under Rule 10a-5 under the Trust Indenture Act of 1939. The Filer stipulates and agrees that any such civil suit or action or administrative proceeding may be commenced by the service of process upon, and that service of an administrative subpoena shall be effected by service upon such agent for service of process, and that service as aforesaid shall be taken and held in all courts and administrative tribunals to be valid and binding as if personal service thereof had been made.

F. Each person filing this Form in connection with:

(a) the use of Form F-9, F-10, 40-F, or SB-2 or Schedule 13E-4F, 14D-1F or 14D-9F stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed from the date the issuer of the securities to which such Forms and Schedules relate has ceased reporting under the Exchange Act;

(b) the use of Form F-8, Form F-80 or Form CB stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed following the effective date of the latest amendment to such Form F-8, Form F-80 or Form CB;

(c) its status as trustee with respect to securities registered on Form F-7, F-8, F-9, F-10, F-80, or SB-2 stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time during which any of the securities subject to the indenture remain outstanding; and


(d) the use of Form 1-A or other Commission form for an offering pursuant to Regulation A stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed from the date of the last sale of securities in reliance upon the Regulation A exemption.

Each filer further undertakes to advise the Commission promptly of any change to the Agent's name or address during the applicable period by amendment of this Form, referencing the file number of the relevant form in conjunction with which the amendment is being filed.

G. Each person filing this Form, other than a trustee filing in accordance with General Instruction I.(a) of this Form, undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to: the Forms, Schedules and offering statements described in General Instructions I.(a), I. (b), I.(c), I.(d) and I.(f) of this Form, as applicable; the securities to which such Forms, Schedules and offering statements relate; and the transactions in such securities.

The Filer certifies that it has duly caused this power of attorney, consent, stipulation and agreement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Hørsholm
Country of Denmark this 4 day of January,
2008.

Filer: Pharmexa A/S


By: Jakob Schmidt
Title: Chief Executive Officer

This statement has been signed by the following persons in the capacities and on the dates indicated.

CT Corporation System


Name: _____

Title: _____

Date: January 7, 2008

Sohan R. Dindyal
Assistant Secretary

BOARD RESOLUTION

In connection with the contemplated issue of a minimum of 10,000,000 shares and up to a maximum of 69.090.658 shares of DKK 5 each with a total nominal value of minimum DKK 50,000,000 and up to maximum DKK 345,453,290 (the "Shares") to be decided by a board meeting it was resolved that:

1. the entering into and execution by Pharmexa A/S of a Rights Issue Agreement expected to be dated 9 January 2008 between Pharmexa A/S and Danske Markets (a division of Danske Bank) including the fixing of an Offer Price for the Shares (a draft of which has been approved by the Board);
2. the issue of Offering Circulars (one edition in the English and one in the Danish language) expected to be dated 9 January 2008;
3. the making, signing, execution and delivery of such other notes, deeds, agreements, letters, notices, certificates, acknowledgements, instructions, decisions and other documents (whether of a like nature or not) necessary in connection with the issue of the Shares, the signing of the Rights Issue Agreement and/or the issue of the Offering Circulars ("Ancillary Documents"); be and is hereby approved.
4. It was further resolved that each of Ole Steen Andersen and Jakob Schmidt shall alone be authorised to sign the Rights Issue Agreement referred to under Clause 1 above, any Ancillary Documents referred to in Clause 3 above, including but not limited to Forms CB and F-X to the SEC, on behalf of the Company.

Date: January 9, 2008

The board of directors:


Ole Steen Andersen

Karen Lykke Sørensen

Alf A. Lindberg

Tomas Brink Wikborg

Jørgen Buus Lassen



Michel L. Pettigrew

Karl Olof Borg

Finn Stausholm Nielsen

Certified copy
Pharmexa A/S
Kogle Allé 6
DK-2970 Horsholm
Tel +45 45 16 25 25
Fax +45 45 16 25 00
SE nr. DK 14538372

BOARD RESOLUTION

In connection with the contemplated issue of a minimum of 10,000,000 shares and up to a maximum of 69.090.658 shares of DKK 5 each with a total nominal value of minimum DKK 50,000,000 and up to maximum DKK 345,453,290 (the "Shares") to be decided by a board meeting it was resolved that:

1. the entering into and execution by Pharmexa A/S of a Rights Issue Agreement expected to be dated 9 January 2008 between Pharmexa A/S and Danske Markets (a division of Danske Bank) including the fixing of an Offer Price for the Shares (a draft of which has been approved by the Board);
2. the issue of Offering Circulars (one edition in the English and one in the Danish language) expected to be dated 9 January 2008;
3. the making, signing, execution and delivery of such other notes, deeds, agreements, letters, notices, certificates, acknowledgements, instructions, decisions and other documents (whether of a like nature or not) necessary in connection with the issue of the Shares, the signing of the Rights Issue Agreement and/or the issue of the Offering Circulars ("Ancillary Documents"); be and is hereby approved.
4. It was further resolved that each of Ole Steen Andersen and Jakob Schmidt shall alone be authorised to sign the Rights Issue Agreement referred to under Clause 1 above, any Ancillary Documents referred to in Clause 3 above, including but not limited to Forms CB and F-X to the SEC, on behalf of the Company.

Date: January 9, 2008


The board of directors:

Ole Steen Andersen

Jørgen Buus Lassen

Karen Lykke Sørensen

Michel L. Pettigrew



Alf A. Lindberg

Karl Olof Borg

Tomas Brink Wikborg

Pinn Stausholm Nielsen

Certified copy
Pharmexa A/S
Kogle Allé 6
DK-2970 Hørsholm
Tel +45 45 16 25 25
Fax +45 45 16 25 00
SE nr. DK 14538372

BOARD RESOLUTION

In connection with the contemplated issue of a minimum of 10,000,000 shares and up to a maximum of 69.090.658 shares of DKK 5 each with a total nominal value of minimum DKK 50,000,000 and up to maximum DKK 345,453,290 (the "Shares") to be decided by a board meeting it was resolved that:

1. the entering into and execution by Pharmexa A/S of a Rights Issue Agreement expected to be dated 9 January 2008 between Pharmexa A/S and Danske Markets (a division of Danske Bank) including the fixing of an Offer Price for the Shares (a draft of which has been approved by the Board);
2. the issue of Offering Circulars (one edition in the English and one in the Danish language) expected to be dated 9 January 2008;
3. the making, signing, execution and delivery of such other notes, deeds, agreements, letters, notices, certificates, acknowledgements, instructions, decisions and other documents (whether of a like nature or not) necessary in connection with the issue of the Shares, the signing of the Rights Issue Agreement and/or the issue of the Offering Circulars ("Ancillary Documents"); be and is hereby approved.
4. It was further resolved that each of Ole Steen Andersen and Jakob Schmidt shall alone be authorised to sign the Rights Issue Agreement referred to under Clause 1 above, any Ancillary Documents referred to in Clause 3 above, including but not limited to Forms CB and F-X to the SEC, on behalf of the Company.

Date: January 9, 2008

The board of directors:


Ole Steen Andersen

Jørgen Buus Lassen

Karen Lykke Sørensen

Michel L. Pettigrew

Alf A. Lindberg




Karl Olof Borg

Tomas Brink Wikborg

Finn Stausholm Nielsen

Pharmexa A/S

Kogle Allé 6
DK-2970 Hørsholm
Tel +45 45 16 25 25
Fax +45 45 16 25 00
SE nr. DK 14538372

*Certified
copy*



BOARD RESOLUTION

In connection with the contemplated issue of a minimum of 10,000,000 shares and up to a maximum of 69.090.658 shares of DKK 5 each with a total nominal value of minimum DKK 50,000,000 and up to maximum DKK 345,453,290 (the "Shares") to be decided by a board meeting it was resolved that:

1. the entering into and execution by Pharmexa A/S of a Rights Issue Agreement expected to be dated 9 January 2008 between Pharmexa A/S and Danske Markets (a division of Danske Bank) including the fixing of an Offer Price for the Shares (a draft of which has been approved by the Board);
2. the issue of Offering Circulars (one edition in the English and one in the Danish language) expected to be dated 9 January 2008;
3. the making, signing, execution and delivery of such other notes, deeds, agreements, letters, notices, certificates, acknowledgements, instructions, decisions and other documents (whether of a like nature or not) necessary in connection with the issue of the Shares, the signing of the Rights Issue Agreement and/or the issue of the Offering Circulars ("Ancillary Documents"); be and is hereby approved.
4. It was further resolved that each of Ole Steen Andersen and Jakob Schmidt shall alone be authorised to sign the Rights Issue Agreement referred to under Clause 1 above, any Ancillary Documents referred to in Clause 3 above, including but not limited to Forms CB and F-X to the SEC, on behalf of the Company.

Date: January 9, 2008

The board of directors:



Ole Steen Andersen

Jørgen Buus Lassen

Karen Lykke Sørensen

Michel L. Pettigrew

Alf A. Lindberg

Karl Olof Borg

Tomas Brink Wikborg

Finn Stausholm Nielsen

Certified copy
Pharmexa A/S
Kogle Allé 6
DK-2970 Hørsholm
Tel +45 45 16 25 25
Fax +45 45 16 25 00
SE nr. DK 14538372



BOARD RESOLUTION

In connection with the contemplated issue of a minimum of 10,000,000 shares and up to a maximum of 69.090.658 shares of DKK 5 each with a total nominal value of minimum DKK 50,000,000 and up to maximum DKK 345,453,290 (the "Shares") to be decided by a board meeting it was resolved that:

1. the entering into and execution by Pharmexa A/S of a Rights Issue Agreement expected to be dated 9 January 2008 between Pharmexa A/S and Danske Markets (a division of Danske Bank) including the fixing of an Offer Price for the Shares (a draft of which has been approved by the Board);
2. the issue of Offering Circulars (one edition in the English and one in the Danish language) expected to be dated 9 January 2008;
3. the making, signing, execution and delivery of such other notes, deeds, agreements, letters, notices, certificates, acknowledgements, instructions, decisions and other documents (whether of a like nature or not) necessary in connection with the issue of the Shares, the signing of the Rights Issue Agreement and/or the issue of the Offering Circulars ("Ancillary Documents"); be and is hereby approved.
4. It was further resolved that each of Ole Steen Andersen and Jakob Schmidt shall alone be authorised to sign the Rights Issue Agreement referred to under Clause 1 above, any Ancillary Documents referred to in Clause 3 above, including but not limited to Forms CB and F-X to the SEC, on behalf of the Company.

Date: January 9, 2008


The board of directors:

Ole Steen Andersen

Karen Lykke Sørensen

Alf A. Lindberg

Tomas Brink Wikborg



Jørgen Buus Lassen

Michel L. Pettigrew

Karl Olof Borg

Finn Stausholm Nielsen

Certified copy
Pharmexa A/S

Kogle Allé 6
DK-2970 Horsholm
Tel +45 45 16 25 15
Fax +45 45 16 25 00
SE nr. DK 14538872

BOARD RESOLUTION

In connection with the contemplated issue of a minimum of 10,000,000 shares and up to a maximum of 69.090.658 shares of DKK 5 each with a total nominal value of minimum DKK 50,000,000 and up to maximum DKK 345,453,290 (the "Shares") to be decided by a board meeting it was resolved that:

1. the entering into and execution by Pharmexa A/S of a Rights Issue Agreement expected to be dated 9 January 2008 between Pharmexa A/S and Danske Markets (a division of Danske Bank) including the fixing of an Offer Price for the Shares (a draft of which has been approved by the Board);
2. the issue of Offering Circulars (one edition in the English and one in the Danish language) expected to be dated 9 January 2008;
3. the making, signing, execution and delivery of such other notes, deeds, agreements, letters, notices, certificates, acknowledgements, instructions, decisions and other documents (whether of a like nature or not) necessary in connection with the issue of the Shares, the signing of the Rights Issue Agreement and/or the issue of the Offering Circulars ("Ancillary Documents"); be and is hereby approved.
4. It was further resolved that each of Ole Steen Andersen and Jakob Schmidt shall alone be authorised to sign the Rights Issue Agreement referred to under Clause 1 above, any Ancillary Documents referred to in Clause 3 above, including but not limited to Forms CB and F-X to the SEC, on behalf of the Company.

Date: January 9, 2008

The board of directors:

Ole Steen Andersen

Jørgen Buus Lassen

Karen Lykke Sørensen

Michel L. Pettigrew

Alf A. Lindberg

Karl Olof Borg

Tomas Brink Wikborg

Finn Stausholm Nielsen

Pharmexa A/S
Køge Allé 8
DK-2970 Hørsholm
Tel +45 45 16 75 25
Fax +45 45 16 75 00
SE nr. DK 1453372

BOARD RESOLUTION


In connection with the contemplated issue of a minimum of 10,000,000 shares and up to a maximum of 69.090.658 shares of DKK 5 each with a total nominal value of minimum DKK 50,000,000 and up to maximum DKK 345,453,290 (the "Shares") to be decided by a board meeting it was resolved that:

1. the entering into and execution by Pharmexa A/S of a Rights Issue Agreement expected to be dated 9 January 2008 between Pharmexa A/S and Danske Markets (a division of Danske Bank) including the fixing of an Offer Price for the Shares (a draft of which has been approved by the Board);
2. the issue of Offering Circulars (one edition in the English and one in the Danish language) expected to be dated 9 January 2008;
3. the making, signing, execution and delivery of such other notes, deeds, agreements, letters, notices, certificates, acknowledgements, instructions, decisions and other documents (whether of a like nature or not) necessary in connection with the issue of the Shares, the signing of the Rights Issue Agreement and/or the issue of the Offering Circulars ("Ancillary Documents"); be and is hereby approved.
4. It was further resolved that each of Ole Steen Andersen and Jakob Schmidt shall alone be authorised to sign the Rights Issue Agreement referred to under Clause 1 above, any Ancillary Documents referred to in Clause 3 above, including but not limited to Forms CB and F-X to the SEC, on behalf of the Company.

Date: January 9, 2008

The board of directors:

Ole Steen Andersen



Karen Lykke Sørensen

Alf A. Lindberg

Tomas Brink Wikborg

Jørgen Buus Lassen

Michel L. Pettigrew

Karl Olof Borg

Finn Stausholm Nielsen

Certified copy
Pharmexa A/S
Kogle Allé 6
DK-2970 Hørsholm
Tel +45 45 16 25 25
Fax +45 45 16 25 00
SE nr. DK 14538372

END